当前位置:公众访问 >页面
简体中文 / English
1.Screening
1.1.Management for Progress
1.2.Inclusion Criteria

Diagnosed as lymphoma with pathological evidences.

yes

Patients that have indications for APBSCT and are willing to have transplantation;

yes

Age 18-60 years;

50 y

ECOG ≤3

yes

Normal organ functions should satisfy:

liver function: ALT, AST, TBIL≤ twice of the normal maximum
/
renal function: BUN, Cr≤1.5 times of the normal maximum

No contraindications for chemotherapy

yes

Patients should sign the written consent before enrollment of the trial, and the written consent should consent all the contents of the trial;

yes

Willing to follow the therapeutic plan, the follow-up plan and take the corresponding lab examinations

yes

1.3.Exclusion Criteria

Contra-indications for chemotherapy

no

Patients with severe organ impairment: including respiratory failure, heart failure of degree II and beyond, decompensated liver failure, renal failure; uncontrolled hypertention or diabetes, severe diabetic retinal disease;

no

Use of cytokines beside G-CSF within 3 weeks prior to enrollment

no

Uncontrolled infection;

no

History of severe rhTPO allergy

no

Women during pregnancy or lactation

no

Patients that are participating other trials

no

Patients with other severe acute/chronic physical or mental disorders, or with abnormal lab tests that may impair drug administration or influence the researchers’ evaluation, or influence the explanation about the results.

no

2.Baseline
2.1.Management of the progress
2.2.General information

Gender

Male

Age

50 y

2.3.Physical examination

Body Surface Area

1.846 m2

2.4.Stage of Disease

IIB

2.5.Disease Condition

PR

2.6.Group

Experiment Group

2.7.Coagulation Function Tests
2.8.Serum Liver Function Tests
2.9.HBV Markers Test
2.10.Renel Function Test
2.11.Heat Function Examination
2.12.Blood Cell Morphology
2.13.Image Examinations
2.14.Nervous System Examination
2.15.Lung Function Examination
2.16.Blood Gas Analysis
2.17.Physical Ability Examination
2.18.Health Relative Quality of Life
3.In the process of the treatment
3.1.Treatment Record

Total Amount of CD34+ cells collected

2.46 10^6

Amount of Mononucleated cells collected

5.0 10^6

1.3.4.Uncontrolled infection;
4.At the end of the treatment
4.1.Management for Progress
4.2.Myeloid Linage Inplantation Date

15 d

4.3.Blood Routine Tests
4.4.Urine and Stool Routine Tests
4.5.Serum Electrolytes Tests
4.6.Liver Function Tests
4.7.HBV Markers Test
4.8.Renel Function Test
4.9.Heat Function Examination
4.10.Image Examinations
4.11.Blood Cell Morphology
4.12.Nervous System Examination
4.13.Lung Function Examination
4.14.Blood Gas Analysis
4.15.Physical Sbility Examination
4.16.Health Relative Quality of Life
5.Follow-up 1
1.Blood routine test
6.Follow-up 2
7.Follow-up 3
8.Management system of participants
9.Speciman management system
10.Data management system
11.ADR/ADE management system
12.Madicine management system
13.Instruments management system
14.SOPs
14.1.Treatment SOP
14.2.Nursing SOP
14.3.Specimen collection SOP
15.Research team
15.1.Institutions
15.2.Researchers
16.Design, Methods
16.1.Calculation of sample size